The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors
Open accessAbstract
We developed a high-throughput HTRF (homogeneous time-resolved fluorescence) assay for Akt kinase activity and screened approx. 270000 compounds for their ability to inhibit the three isoforms of Akt. Two Akt inhibitors were identified that exhibited isoenzyme specificity. The first compound (Akt-I-1) inhibited only Akt1 (IC50 4.6 μM) while the second compound (Akt-I-1,2) inhibited both Akt1 and Akt2 with IC50 values of 2.7 and 21 μM respectively. Neither compound inhibited Akt3 nor mutants lacking the PH (pleckstrin homology) domain at concentrations up to 250 μM. These compounds were reversible inhibitors, and exhibited a linear mixed-type inhibition against ATP and peptide substrate. In addition to inhibiting kinase activity of individual Akt isoforms, both inhibitors blocked the phosphorylation and activation of the corresponding Akt isoforms by PDK1 (phosphoinositide-dependent kinase 1). A model is proposed in which these inhibitors bind to a site formed only in the presence of the PH domain. Binding of the inhibitor is postulated to promote the formation of an inactive conformation. In support of this model, antibodies to the Akt PH domain or hinge region blocked the inhibition of Akt by Akt-I-1 and Akt-I-1,2. These inhibitors were found to be cell-active and to block phosphorylation of Akt at Thr308 and Ser473, reduce the levels of active Akt in cells, block the phosphorylation of known Akt substrates and promote TRAIL (tumour-necrosis-factor-related apoptosis-inducing ligand)-induced apoptosis in LNCap prostate cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 2,826
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
Liaw, D., Marsh, D. J., Li, J., Dahia, P. L. M., Wang, S. I., Zheng, Z., Bose, S., Call, K. M., Tsou, H. C., Peacoke, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-64 · Cited by 2,091
Cho, H., Mu, J., Kim, J. K., Thorvaldsen, J. L., Chu, Q., Crenshaw, E. B., Kaestner, K. H., Bartolomei, M. S., Shulman, G. I., & Birnbaum, M. J. (2001) · Science · doi:10.1126/science.292.5522.1728 · Cited by 1,836
The PI3K‒PDK1 connection: more than just a road to PKB
Vanhaesebroeck, B., & Alessi, D. R. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3460561 · Cited by 1,644
Three-dimensional structure of the tyrosine kinase c-Src
Xu, W., Harrison, S. C., & Eck, M. J. (1997) · Nature · doi:10.1038/385595a0 · Cited by 1,418
Dual Role of Phosphatidylinositol-3,4,5-trisphosphate in the Activation of Protein Kinase B
Stokoe, D., Stephens, L. R., Copeland, T., Gaffney, P. R. J., Reese, C. B., Painter, G. F., Holmes, A. B., McCormick, F., & Hawkins, P. T. (1997) · Science · doi:10.1126/science.277.5325.567 · Cited by 1,201
Ten years of protein kinase B signalling: a hard Akt to follow
Brazil, D. P., & Hemmings, B. A. (2001) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(01)01958-2 · Cited by 1,177
Crystal structure of the Src family tyrosine kinase Hck
Sicheri, F., Moarefi, I., & Kuriyan, J. (1997) · Nature · doi:10.1038/385602a0 · Cited by 1,172
cAMP-DEPENDENT PROTEIN KINASE: FRAMEWORK FOR A DIVERSE FAMILY OF REGULATORY ENZYMES
Taylor, S. S., Buechler, J. A., & Yonemoto, W. (1990) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.59.070190.004543 · Cited by 1,144
Cho, H., Thorvaldsen, J. L., Chu, Q., Feng, F., & Birnbaum, M. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100462200 · Cited by 959
Crystal structure of the p27Kip1 cyclin-dependent-kinase inibitor bound to the cyclin A–Cdk2 complex
Russo, A. A., Jeffrey, P. D., Patten, A. K., Massagué, J., & Pavletich, N. P. (1996) · Nature · doi:10.1038/382325a0 · Cited by 907
Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S., et al. (2002) · Nature Structural Biology · doi:10.1038/nsb770 · Cited by 833
Staal, S. P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.14.5034 · Cited by 767
Mechanism of activation and function of protein kinase B
Alessi, D. R., & Cohen, P. (1998) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(98)80062-2 · Cited by 743
Chan, T. O., Rittenhouse, S. E., & Tsichlis, P. N. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.965 · Cited by 737
PTEN: Life as a Tumor Suppressor
Simpson, L., & Parsons, R. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5130 · Cited by 679
Marsh, D. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.3.507 · Cited by 653
Crystal structure of an activated Akt/Protein Kinase B ternary complex with GSK3-peptide and AMP-PNP
Yang, J., Cron, P., Good, V. M., Thompson, V., Hemmings, B. A., & Barford, D. (2002) · Nature Structural Biology · doi:10.1038/nsb870 · Cited by 503
Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease
Kwon, C.-H., Zhu, X., Zhang, J., Knoop, L. L., Tharp, R., Smeyne, R. J., Eberhart, C. G., Burger, P. C., & Baker, S. J. (2001) · Nature Genetics · doi:10.1038/ng781 · Cited by 478
Nakatani, K., Thompson, D. A., Barthel, A., Sakaue, H., Liu, W., Weigel, R. J., & Roth, R. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21528 · Cited by 475
Molecular Mechanism for the Regulation of Protein Kinase B/Akt by Hydrophobic Motif Phosphorylation
Yang, J., Cron, P., Thompson, V., Good, V. M., Hess, D., Hemmings, B. A., & Barford, D. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00550-6 · Cited by 418
PTEN: from pathology to biology
Sulis, M. (2003) · Trends in Cell Biology · doi:10.1016/s0962-8924(03)00175-2 · Cited by 344
Mutations of the human PTEN gene
Bonneau, D., & Longy, M. (2000) · Human Mutation · doi:10.1002/1098-1004(200008)16:2<109::aid-humu3>3.0.co;2-0 · Cited by 333
Chemical Inhibitors of Protein Kinases
Bridges, A. J. (2001) · Chemical Reviews · doi:10.1021/cr000250y · Cited by 320
Madhusudan, Trafny, E. A., Xuong, N., Adams, J. A., Eyck, L. F. T., Taylor, S. S., & Sowadski, J. M. (1994) · Protein Science · doi:10.1002/pro.5560030203 · Cited by 274
Elevated Akt Activity Protects the Prostate Cancer Cell Line LNCaP from TRAIL-induced Apoptosis
Nesterov, A., Lu, X., Johnson, M., Miller, G. J., Ivashchenko, Y., & Kraft, A. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m005196200 · Cited by 269
The Akt Pathway: Molecular Targets for Anti-Cancer Drug Development
Mitsiades, C., Mitsiades, N., & Koutsilieris, M. (2004) · Current Cancer Drug Targets · doi:10.2174/1568009043333032 · Cited by 253
Zhou, X.-P., Hampel, H., Thiele, H., Gorlin, R. J., Hennekam, R. C., Parisi, M., Winter, R. M., & Eng, C. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05412-5 · Cited by 225
Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis.
Page, C., Lin, H., Jin, Y. H., et al. (2000) · PubMed · Cited by 220
Complexes of polyoma virus medium T antigen and cellular proteins.
Grussenmeyer, T., Scheidtmann, K. H., Hutchinson, M. A., Eckhart, W., & Walter, G. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.23.7952 · Cited by 217
ErbB-targeted therapeutic approaches in human cancer
Arteaga, C. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00104-0 · Cited by 215
Molecular cloning, expression and characterization of the human serine/threonine kinase Akt‐3
Masure, S., Haefner, B., Wesselink, J., Hoefnagel, E., Mortier, E., Verhasselt, P., Tuytelaars, A., Gordon, R., & Richardson, A. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00774.x · Cited by 159
Arch, E. M., Goodman, B. K., Wesep, R. V., Liaw, D., Clarke, K. A., Parsons, R., Mckusick, V. A., & Geraghty, M. T. (1997) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19970905)71:4<489::aid-ajmg24>3.3.co;2-i · Cited by 140
PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis
Besson, A., Robbins, S. M., & Yong, V. W. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00542.x · Cited by 130
ATP site-directed competitive and irreversible inhibitors of protein kinases
Garc�a-Echeverr�a, C., Traxler, P. M., & Evans, D. B. (2000) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(200001)20:1<28::aid-med2>3.0.co;2-2 · Cited by 124
Demetri, G. D. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80603-7 · Cited by 117
Structural Basis of the Intrasteric Regulation of Myosin Light Chain Kinases
Knighton, D. R., Pearson, R. B., Sowadski, J. M., Means, A. R., Eyck, L. F. T., Taylor, S. S., & Kemp, B. E. (1992) · Science · doi:10.1126/science.1439761 · Cited by 113
Structural biology in drug design: selective protein kinase inhibitors
Scapin, G. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02290-0 · Cited by 107
Giant protein kinases: domain interactions and structural basis of autoregulation.
Kobe, B., Heierhorst, J., Feil, S. C., Parker, M. W., Benian, G. M., Weiss, K. R., & Kemp, B. E. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01072.x · Cited by 106
Differential Regulation of Akt Kinase Isoforms by the Members of the TCL1 Oncogene Family
Laine, J. T., Künstle, G., Obata, T., & Noguchi, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107069200 · Cited by 99
Tyrosine kinase assays adapted to homogeneous time-resolved fluorescence
Kolb, A. J., Kaplita, P. V., Hayes, D. J., Park, Y.-W., Pernell, C., Major, J. S., & Mathis, G. (1998) · Drug Discovery Today · doi:10.1016/s1359-6446(98)01204-5 · Cited by 78
Protein kinase inhibitors: emerging pharmacophores 1997 - 2000
Dumas, J. (2001) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.11.3.405 · Cited by 71
Protein kinase inhibition: natural and synthetic variations on a theme
Taylor, S. S., & Radzio-Andzelm, E. (1997) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(97)80013-0 · Cited by 54
Rokhlin, O. W., Guseva, N. V., Taghiyev, A. F., Glover, R. A., & Cohen, M. B. (2002) · The Prostate · doi:10.1002/pros.10074 · Cited by 40
Arteaga, C. L. (2003) · PubMed · Cited by 20
Cited by
AKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
The selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,520
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,292
Metadata
- Authors
- BARNETT, S. F., DEFEO-JONES, D., FU, S., HANCOCK, P. J., HASKELL, K. M., JONES, R. E., KAHANA, J. A., KRAL, A. M., LEANDER, K., LEE, L. L., MALINOWSKI, J., McAVOY, E. M., NAHAS, D. D., ROBINSON, R. G., & HUBER, H. E.
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 2005-01-07
- Volume
- 385
- Issue
- 2
- Pages
- 399-408
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- OpenAlex
- W2060818930
- Cited by
- 396
- References
- 52
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.